ReviewParkinson's disease2019
MicroRNAs: Game Changers in the Regulation of
Review in Parkinson's disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Deregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria.Ageing research reviews · 2022Pooled it
- Molecular crosstalk between miRNAs and lncRNAs in neurodegenerative disease pathways.Molecular biology reports · 2025Review
- Cohort-specific boolean models highlight different regulatory modules during Parkinson's disease progression.iScience · 2024Article
- Association of Serum Extracellular Vesicle miRNAs with Cognitive Functioning and Quality of Life in Parkinson's Disease.Biomolecules · 2024Article
- Neuroinflammation in Parkinson's disease: focus on the relationship between miRNAs and microglia.Frontiers in cellular neuroscience · 2024Review
- Epigenetics: the missing link between environmental exposures and Parkinson's disease?Epigenomics · 2024Article
- Article
- MicroRNA: A Linking between Astrocyte Dysfunction, Mild Cognitive Impairment, and Neurodegenerative Diseases.Life (Basel, Switzerland) · 2022Review
- Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.Metabolic brain disease · 2022Review
- Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration.Current neuropharmacology · 2022Review
- Alpha-Synuclein and Cognitive Decline in Parkinson Disease.Life (Basel, Switzerland) · 2021Review
- Exploring the Role of Autophagy Dysfunction in Neurodegenerative Disorders.Molecular neurobiology · 2021Review
- RNA pull-down confocal nanoscanning (RP-CONA) detects quercetin as pri-miR-7/HuR interaction inhibitor that decreases α-synuclein levels.Nucleic acids research · 2021Article
- MicroRNAs, Parkinson's Disease, and Diabetes Mellitus.International journal of molecular sciences · 2021Review
- Evolutionary Changes in the Interaction of miRNA With mRNA of Candidate Genes for Parkinson's Disease.Frontiers in genetics · 2021Article
- MiRNA Expression in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy.Life (Basel, Switzerland) · 2020Article
- MicroRNA‑199a‑5p suppresses cell proliferation, migration and invasion by targeting ITGA3 in colorectal cancer.Molecular medicine reports · 2020Article
- MiR-301a promotes embryonic stem cell differentiation to cardiomyocytes.World journal of stem cells · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second most common neurodegenerative disorder. Its neuropathological hallmarks include neuronal loss in the substantia nigra pars compacta (SNpc) and the presence of Lewy bodies containing aggregates of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.